Phase ii/iii clinical trial to assess the tolerability and immunological effect of a new updosing phase of dermatophagoides mix–based immunotherapy

Journal of Investigational Allergology and Clinical Immunology

Volumn 25, Issue 1, 2015, Pages 40-46

  Tabar, A I ^a   Gonzalez Delgado P ^b   Sanchez Hernandez C ^c   Basagana Torrento M ^d   Moreno Benitez F ^e   Arina, María ^f  

^a Instituto de Investigación Sanitaria de Navarra   (Spain)

^b Alicante Hospital   (Spain)

^c CPE Virgen de la Cinta   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e Clinica Dr Lobaton   (Spain)

^f ALK ABELLÓ   (Denmark)

Author keywords

Allergens; Antigens; House dust mites; Immune response; Skin reactivity; Specific immunotherapy; Subcutaneous injection; Tolerability assessment

Indexed keywords

DERMATOPHAGOIDES MIX; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; UNCLASSIFIED DRUG; ALLERGEN; IMMUNOGLOBULIN G;

ADULT; ALLERGIC RHINITIS; ARTICLE; COUGHING; DERMATOPHAGOIDES; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DRUG TOLERABILITY; DYSPNEA; FEMALE; FOLLOW UP; HEADACHE; HUMAN; IMMUNOASSAY; IMMUNOTHERAPY; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NOSE OBSTRUCTION; ORAL PARESTHESIA; ORAL PRURITUS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RHINOCONJUNCTIVITIS; SKIN MANIFESTATION; SKIN TEST; TACHYCARDIA; ADVERSE EFFECTS; ANIMAL; ASTHMA; CLINICAL TRIAL; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION; IMMUNOLOGY; PROCEDURES; RHINITIS, ALLERGIC; YOUNG ADULT;

ADULT; ALLERGENS; ANIMALS; ASTHMA; CONJUNCTIVITIS, ALLERGIC; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MALE; RHINITIS, ALLERGIC; YOUNG ADULT;

EID: 84923563865     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ozdoganoglu T, Songu M. The burden of allergic rhinitis and asthma. Ther Adv Respir Dis. 2012;6(1):11-23.
2. Linneberg A, Nielsen NH, Madsen F, Frolund L, Dirksen A, Jorgensen T. Secular trends of allergic asthma in Danish adults. The Copenhagen Allergy Study. Respir Med. 2001;95(4):258-64.
3. Platts-Mills TA, Vervloet D, Thomas WR, Aalberse RC, Chapman MD. Indoor allergens and asthma: report of the Third International Workshop. J Allergy Clin Immunol. 1997;100(6 Pt 1):S2-24.
4. Terreehorst I, Oosting AJ, Tempels-Pavlica Z, de Monchy JG, Bruijnzeel-Koomen CA, Hak E, van Wijk RG. Prevalence and severity of allergic rhinitis in house dust mite-allergic patients with bronchial asthma or atopic dermatitis. Clin Exp Allergy. 2002;32(8):1160-5.
5. Bousquet J, Van CP, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 Suppl):S147-S334.
6. Olaguibel JM, Tabar AI, Garcia BE, Martin S, Rico P. Longterm immunotherapy with an optimal maintenance dose of a standardized Dermatophagoides pteronyssinus extract in asthmatic patients. J Investig Allergol Clin Immunol. 1999;9(2):110-6.
7. Tabar AI, Arroabarren E, Echechipia S, Garcia BE, Martin S, Alvarez-Puebla MJ. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol. 2011;127(1):57-63, 63.
8. Rask C, Lund L, Lund G, Urioste S, Thorup S, Bergmann K, Lund K. Optimised allergen: adjuvant ratio potentiates immunogenicity of AlOH-formulated Phleum pratense extract. Allergy. 2010;65(Issue Supplement s92):175.
9. World Medical Association. The Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Updated 2002. [cited 5-7-2013]. Available from: http://www.fda.gov/ohrms/dockets/dockets/06d0331/06D-0331-EC20-Attach-1.pdf.
10. ICH Harmonised Tripartite Guideline E6 S5. Guideline for Good Clinical Practice. 1996.
11. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergenspecific immunotherapy. Allergy. 2006;61 Suppl 82:1-20.
12. Lee RE, Smolensky MH, Leach CS, McGovern JP. Circadian rhythms in the cutaneous reactivity to histamine and selected antigens, including phase relationship to urinary cortisol excretion. Ann Allergy. 1977;38(4):231-6.
13. Malling HJ, Weeke B. Position Paper: Immunotherapy. Allergy, European Journal of Allergy and Clinical Immunology. 1993;48(Supplement s14):9-35.
14. Committee for Medicinal Products for Human Use. Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases. CHMP/ EWP/18504/2006
15. Pfaar O, Jung K, Wolf H, Decot E, Kleine-Tebbe J, Klimek L, Wustenberg E. Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio. Allergy. 2012;67(5):630-7.
16. Tabar AI, Garcia BE, Rodriguez A, Olaguibel JM, Muro MD, Quirce S. A prospective safety-monitoring study of immunotherapy with biologically standardized extracts. Allergy. 1993;48(6):450-3.
17. Olaguibel JM, Tabar AI, Garcia Figueroa BE, Cortes C. Immunotherapy with standardized extract of Dermatophagoides pteronyssinus in bronchial asthma: a dose-titration study. Allergy. 1997;52(2):168-78.
18. Tabar AI, Echechipia S, Garcia BE, Olaguibel JM, Lizaso MT, Gomez B, Aldunate MT, Martin S, Marcotegui F. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol. 2005;116(1):109-18.
19. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2007;119(4):780-91.
20. Shamji MH, Ljorring C, Francis JN, Calderon MA, Larche M, Kimber I, Frew AJ, Ipsen H, Lund K, Wurtzen PA, Durham SR. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy. 2012;67(2):217-26.
21. Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol. 2004;4(4):313-8.
22. Vidal C, Tabar AI, Figueroa J, Navarro JA, Sanchez C, Orovitg A, Armisen M, Echechipia S, Joral A, Lizarza S, Lizaso MT, Rodriguez V, de la Torre F. Assessment of short-term changes induced by a Dermatophagoides pteronyssinus extract on asthmatic patients. Randomised, double-blind, placebocontrolled trial. Curr Drug Deliv. 2011;8(2):152-8.
23. Martin S, Cuesta P, Rico P, Cortes C. A computer program based on parallel line assay for analysis of skin tests. Allergy. 1997;52(1):97-100.
24. Bousquet J, Maasch H, Martinot B, Hejjaoui A, Wahl R, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. II. Comparison between parameters assessing the efficacy of immunotherapy. J Allergy Clin Immunol. 1988;82(3 Pt 1):439-46.